Compare SELX & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SELX | PASG |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | Taiwan | United States |
| Employees | N/A | 27 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.0M | 26.0M |
| IPO Year | 2023 | 2020 |
| Metric | SELX | PASG |
|---|---|---|
| Price | $0.34 | $11.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.80 |
| AVG Volume (30 Days) | ★ 3.3M | 30.3K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.28 |
| 52 Week High | $1.85 | $20.00 |
| Indicator | SELX | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 66.05 |
| Support Level | $0.23 | $6.26 |
| Resistance Level | $0.78 | $20.00 |
| Average True Range (ATR) | 0.11 | 1.23 |
| MACD | 0.00 | 0.50 |
| Stochastic Oscillator | 28.80 | 91.76 |
Semilux International Ltd is a company that operates through its subsidiaries which is an optical and 3D sensing technology company that is involved in the customization, design and supply of optical components and integrated chip for various industries including autonomous driving, intelligent lighting, as well as unmanned aerial vehicles. In collaboration with its clients, TCO conceptualizes and produces high precision optics and sensing modules that are specifically customized to clients' needs for ease of integration in overall design and production. Applications for TCO's products include automotive laser headlight systems, adaptive driving beams (ADB) as well as light detection and autonomous driving systems (LiDAR).
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.